Moberg Pharma AB (publ) (MOB.ST) stock: key figures, P/E, revenue and dividend

Health Care · Biotechnology · Sweden · ISIN SE0020353928

Price
10.94 SEK
Market cap
512.51 m SEK
P/E (2025)
–
P/S (2025)
37.86
Dividend yield
0.00 %
Net margin
-201.18 %
Return on equity (ROE)
-4.09 %
Return on assets (ROA)
-3.99 %

Moberg Pharma AB (publ) financials

Fiscal year20242025
Revenue9.81 m SEK13.54 m SEK
Gross profit6.32 m SEK7.68 m SEK
Operating income-324.83 m SEK-28.00 m SEK
EBIT-320.25 m SEK-28.00 m SEK
Net income-255.11 m SEK-27.24 m SEK
Diluted EPS – continuing operations-6.74 SEK-0.58 SEK

Full history since 2008, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Moberg Pharma AB (publ)

Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It offers MOB-015 for the treatment of nail fungus under the Terclara brand. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. It has license agreement with Karo Healthcare for distribution in European market. Moberg Pharma AB (publ) was incorporated in 2006 and is based in Bromma, Sweden.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.